cytochrome b-245 chaperone 1Genealiases: C17orf62 · CGD5 · Eros
Q-omics provides the consensus-scored CYBC1 profile across patient tissues and cancer cell-line models. CYBC1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CYBC1 is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, CYBC1 protein abundance shows 21,296 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where CYBC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYBC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYBC1 survival associations across molecular data types. CYBC1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYBC1 RNA expression–survival associations across cancer types. High CYBC1 expression shows unfavorable associations in KIRC, ACC and KICH, but favorable associations in HNSC, SKCM and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CYBC1 RNA expression.
This table summarizes CYBC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CYBC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYBC1 shows higher tumor expression in KIRC, HNSC, KIRP, THCA, BLCA and LIHC. The KIRC box plot shows higher CYBC1 RNA expression in tumor versus normal tissue (log2 FC = +1.054, t-test p < 0.001).
This table shows molecular features associated with CYBC1 in patient tissues and cancer cell lines. In patient samples, CYBC1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CYBC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
